Stability of HER-2/neu expression over time and at multiple metastatic sites

Journal of the National Cancer Institute

Volumn 85, Issue 15, 1993, Pages 1230-1235

  Niehans, Gloria A ^a   Singleton, Timothy P ^b   Dykoski, Daniel ^b   Kiang, David T ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR MARKER;

ARTICLE; BREAST CARCINOMA; DISEASE COURSE; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION; GENE TARGETING; GENETIC STABILITY; HUMAN; HUMAN TISSUE; METASTASIS; ONCOGENE; PRIORITY JOURNAL; PROTEIN ANALYSIS;

BREAST NEOPLASMS; FEMALE; HUMAN; IMMUNOENZYME TECHNIQUES; NEOPLASM METASTASIS; ONCOGENE PROTEINS, VIRAL; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; TIME FACTORS;

EID: 0027283498     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/85.15.1230     Document Type: Article

References (58)

1. Slamon, D.J, Clark, G. M., Wong, S. G., et al: Human breast cancer Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182, 1987
2. SCHECHTER A. L., STERN D. F., VaIDYA-nathan L, et al: The neu oncogene: An erb-B-related gene encoding a 185,000-Mr tumour antigen. Nature 312:513-516, 1984.
3. Kino C. R., Kraus M. H., Aaronson S. A.: Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science 229:974-976, 1985.
4. Baromann CI, Hung M-C, Weinberg R. A.: The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature 319:226-230, 1986.
5. Yamamoto T, Ikawa S, Akiyama T, et al: Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor. Nature 319:230-234, 1986.
6. Akiyama, T., Sudo, C. Ooawara, H, et al: The product of the human c-erbB-2 gene: A 185-kilodalton glycoprotein with tyrosine kinase activity. Science 232:1644-1646, 1986
7. Lupu R, Colomer R, Zugmaier G, et al: Direct interaction of a ligand for the erbB2 oncogene product with the EGF receptor and pl85erbB2. Science 249:1552-1555, 1990
8. Peles, E. Bacus, S. S., Koski, R. A., et al: Isolation of the neu/HER-2 stimulatory ligand: A 44 kd glycoprotein that induces differentiation of mammary tumor cells. Cell 69:205-216, 1992.
9. van de Vijver M. J., Peterse J. L., Mooi W. J., et al: Neu-protein overexpression in breast cancer Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage I. I. breast cancer. N Eng J Med 319:1239-1245, 1988.
10. Slamon D. J., Godolphin W, Jones L. A., et al: Studies of the HER-2/neu protooncogene in human breast and ovarian cancer. Science 244:707-712, 1989.
11. Tandon A. K., Clark G. M., Chamness G. C., et al: HER-2/neu oncogene protein and prognosis in breast cancer. J Clin Oncol7:1120-1128, 1989
12. Paik S, Hazan R, Fisher E. R., et al: Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: Prognostic significance of erbB-2 protein overexpression in primary breast cancer. J Clin Oncol 8:103-112, 1990.
13. Paterson M. C., Dietrich K. D., Danyluk J, et al: Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer. Cancer Res51:556-567, 1991
14. Clark G. M., McGuire W. L.: Follow-up study of HER-2/neu amplification in primary breast cancer. Cancer Res 51:944948, 1991
15. Borg A, Baldetorp B, FernO M, et al: ERBB2 amplification in breast cancer with a high rate of proliferation. Oncogene6:137-143, 1991
16. Battifora H, Gaffey M, Esteban J, et al: Immunohistochemical assay of neu/c-erbB-2 oncogene product in paraffin-embedded tissues in early breast cancer: Retrospective follow-up study of 245 stage I and 11 cases. Mod Pathol 4:466-474, 1991.
17. Gusterson B. A., Machin L. G., Gullick W. J., et al: c-erbB-2 expression in benign and malignant breast disease. Br J Cancer58:453-457, 1988
18. Ramachandra S, Machin L, Ashley S, et al: Immunohistochemical distribution of c-erbB-2 in in situ breast carcinoma-a detailed morphological analysis. J Pathol161:7-14, 1990
19. Lodato R. F., Maguire H. C. Jr, Greene M. I., et al: Immunohistochemical evaluation of c-erbB-2 oncogene expression in ductal carcinoma in situ and atypical ductal hyperplasia of the breast. Mod Pathol3:449-454, 1990
20. Allred D. C., Clark G. M., Molina R, et al: Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Hum Pathol 23 974979, 1992
21. Perren T. J.: c-erbB-2 oncogene as a prognostic marker in breast cancer. Br J Cancer 63:328-332, 1991
22. Ali H. J., Campbell G, Lidereau R: Amplification of c-erbB-2 and aggressive human breast tumors? Science 240:1795-1796, 1988
23. Zhou D. J., Ahuja H, Cline M. J.: Protooncogene abnormalities in human breast cancer: c-ERBB-2 amplification does not correlate with recurrence of disease. Oncogene 4:105-108, 1989.
24. Hsu S. M., RaineL, FangerH: Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: A com parison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 29:577-580, 1981.
25. Singleton T. P., Niehans G. A., Gu F, et al: Detection of c-erbB2 activation in paraffin-embedded tissue by immunohistochemistry. Hum Pathol 23:1141-1150, 1992.
26. Wilcoxon F: Individual comparisons by ranking methods. Biometrics Bull 1:80-85, 1945
27. Lacroix H, Iolehart J. D., Skinner M. A., et al: Overexpression of erbB-2 or EGF receptor proteins present in early stage mammary carcinoma is detected simultaneously in matched primary tumors and regional métastasés. Oncogene 4:145-151, 1989
28. Natali P. G., Nicotra M. R., Bioom A, et al: Expression of the pi85 encoded by HER2 oncogene in normal and transformed human tissues. Int J Cancer 45:457-461, 1990
29. Iolehart J. D., Kraus M. H., Lanctton B. C., et al: Increased erbB-2 gene copies and expression in multiple stages of breast cancer. Cancer Res 50:6701-6707, 1990.
30. Barnes D. M., Lammie G. A., Millis R. R., et al: An immunohistochemical evaluation of c-erbB-2 expression in human breast carcinoma. Br J Cancer 58:448-452, 1988.
31. Yokota J, Yamamoto T, Toyoshima K, et al: Amplification of c-erbB-2 oncogene in human adenocarcinomas in vivo. Lancet1:765-767, 1986
32. Maguire H. C. Jr, Hellman M. E., Greene M. I., et al: Expression of c-erbB-2 in in situ and in adjacent invasive ductal adenocarcinomas of the female breast. Pathobiol60:117-121, 1992
33. Fialkow P. J.: Clonal origin of human tumors. Biochim Biophys Acta 458:283-321, 1976
34. Talmadge J. E., Fidler I. J.: Enhanced metastatic potential of tumor cells harvested from spontaneous métastasés of heterogeneous murine tumors. JNCI 69:975-980, 1982
35. Albino A. P., Lloyd K. O., Houghton A. N., et al: Heterogeneity in surface antigen and glycoprotein expression of cell lines derived from different melanoma métastasés of the same patient. Implications for the study of tumor antigens. J Exp Med 154-1764-1778, 1981
36. Brennan M. J., Donegan W. L., Appleby D. E.: The variability of estrogen receptors in metastatic breast cancer. Am J Surg137:260-262, 1979
37. Fuhr J. E., Frye A, Kattine A. A., et al: Flow cytometric determination of breast tumor heterogeneity. Cancer 67:1401-1405, 1991
38. Chen L-C, Kurisu W, Ljung B-M, et al: Heterogeneity for allelic loss in human breast cancer. J Natl Cancer Inst 84:506510, 1992
39. Rofstad E. K., Zaffaroni N, Hystad M. E.: Heterogeneous radiation and heat sensitivity in vitro of human melanoma xenograft lines established from different lesions in the same patient. Comparisons with the radiation and heat sensitivity of cells isolated from the donor patient’s surgical specimens. Int J Radiat Biol 57:1113-1122, 1990.
40. Fugmann R. A., Anderson J. C., Stolfi R. L., et al: Comparison of adjuvant chemotherapeutic activity against primary and metastatic spontaneous murine tumors. Cancer Res 37:496-500, 1977.
41. Heppner G. H., Dexter D. L., DeNucci T, et al: Heterogeneity in drug sensitivity among tumor cell subpopulations of a single mammary tumor. Cancer Res 38:3758-3763, 1978
42. Woodruff M. F.: Cellular heterogeneity in tumours. Br J Cancer 47:589-594, 1983.
43. Heppner G. H.: Tumor heterogeneity Cancer Res 44:2259-2265, 1984.
44. Nicolson G. L.: Tumor cell instability, diversification, and progression to the metastatic phenotype: From oncogene to oncofetal expression. Cancer Res 47-1473- 1487, 1987
45. Kallioniemi O. P., Kallioniemi A, Kurisu W, et al: ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization. Proc Natl Acad Sci USA89:5321-5325, 1992
46. Leitzel K, Teramoto Y, Sampson E, et al: Elevated soluble c-erbB-2 antigen levels in the serum and effusions of a proportion of breast cancer patients. J Clin Oncol10:1436-1443, 1992
47. Sias P. E., Kotts C. E., Vetterlein D, et al: ELISA for quantitation of the extracellular domain of pl85HER2 in biological fluids. J Immunol Methods 132:73-80, 1990.
48. Alper O, Yamaguchi K, Hitomi J, et al: The presence of c-erbB-2 gene product-related protein in culture medium conditioned by breast cancer cell line S. K.-B. R.-3. Cell Growth Diff 1:591-599, 1990.
49. Zabrecky J. R., Lam T, McKenzie S. J., et al: The extracellular domain of pl85/neu is released from the surface of human breast carcinoma cells, S. K.-B. R.-3. J Biol Chem266:1716-1720, 1991
50. McCune C. S., Schapira D. V., Henshaw E. C.: Specific immunotherapy of advanced renal cell carcinoma: Evidence for the poly-clonality of métastasés. Cancer 47:1984-1987, 1981
51. Fendly B. M., Kotts C, Vetterlein D, et al: The extracellular domain of HER2/neu is a potential immunogen for active specific immunotherapy of breast cancer. J Biol Response Mod 9:449-455, 1990.
52. Maier L. A., Xu F. J., Hester S, et al: Requirements for the internalization of a murine monoclonal antibody directed against the HER-2/neu gene product c-erbB-2. Cancer Res 51:5361-5369, 1991.
53. De Santes K, Slamon D, Anderson S. K., et al: Radiolabeled antibody targeting of the HER-2/neu oncoprotein. Cancer Res52:1916-1923, 1992
54. Hudzjak R. M., Lewis G. D., Winget M, et al: pl85-HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol Cell Biol 9:1165-1172, 1989
55. Wada T, Myers J. N., Kokai Y, et al: Anti-receptor antibodies reverse the phenotype of cells transformed by two interacting proto-oncogene encoded receptor proteins. Oncogene 5:489-495, 1990.
56. Tagliabue E, Centis F, Campiolio M, et al: Selection of monoclonal antibodies which induce internalization and phosphorylation of pl85HER2 and growth inhibition of cells with HER2/neu gene amplification. Int 1Cancer 47:933-937, 1991
57. Kasprzyk P. G., Song S. U., Di Fiore P. P., et al: Therapy of an animal model of human gastric cancer using a combination of anti-erbB-2 monoclonal antibodies. Cancer Res52:2771-2776, 1992
58. Brysch W, Magal E, Louis J. C., et al: Inhibiting c-erbB-2 overexpression in human mammary carcinoma cells with phos-phorothioate oligodeoxynucleotides (abstract). Proc Am Assoc Cancer Res32:433, 1991